|
Malignant transformation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Alternatively, CD5 expression could play an additional direct role in malignant transformation as suggested by recent data on the CD5 receptor ligand.
|
1282064 |
1992 |
|
Lymphoma, Non-Hodgkin
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fourteen patients with FSCCL and 1 patient with DSCCL had a phenotype of follicular center cells (FCC) (CALLA+, SIgD-, Leu-1-, Leu-8- and negative ALPase), and 11 patients with FSCCL had bcl-2 gene rearrangements.
|
1643614 |
1992 |
|
Lymphoma, Small Cleaved-Cell, Follicular
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fourteen patients with FSCCL and 1 patient with DSCCL had a phenotype of follicular center cells (FCC) (CALLA+, SIgD-, Leu-1-, Leu-8- and negative ALPase), and 11 patients with FSCCL had bcl-2 gene rearrangements.
|
1643614 |
1992 |
|
Adult Diffuse Small Cleaved Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fourteen patients with FSCCL and 1 patient with DSCCL had a phenotype of follicular center cells (FCC) (CALLA+, SIgD-, Leu-1-, Leu-8- and negative ALPase), and 11 patients with FSCCL had bcl-2 gene rearrangements.
|
1643614 |
1992 |
|
Lymphoma, Follicular, Grade 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fourteen patients with FSCCL and 1 patient with DSCCL had a phenotype of follicular center cells (FCC) (CALLA+, SIgD-, Leu-1-, Leu-8- and negative ALPase), and 11 patients with FSCCL had bcl-2 gene rearrangements.
|
1643614 |
1992 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The leukemic cells from 95% of patients with B cell chronic lymphocytic leukemia (CLL) coexpress B cell differentiation antigens and the pan-T lymphocyte surface antigen CD5 (Leu 1).
|
1689356 |
1990 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The CD5 gene expression was in all cases identical to that of T-cell malignancies.
|
1690580 |
1990 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Malignant CD5 B cells obtained from patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were analyzed for immunoglobulin variable gene usage, CD5 gene expression and autoantibody production.
|
1721931 |
1991 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
We determined that the transcription of the CD5 gene in T cell malignancies, CLL, SLL and a selected group of EBV transformed lines was identical.
|
1721931 |
1991 |
|
Small Lymphocytic Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Malignant CD5 B cells obtained from patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were analyzed for immunoglobulin variable gene usage, CD5 gene expression and autoantibody production.
|
1721931 |
1991 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, we found that the G6 CRI also is expressed frequently by neoplastic CD5 (Leu1) B cells from patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
|
2503826 |
1989 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recently, we found that the G6 CRI also is expressed frequently by neoplastic CD5 (Leu1) B cells from patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
|
2503826 |
1989 |
|
Pleural Effusion, Malignant
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Most of the cells taken from the malignant pleural effusion expressed T cell-associated antigens such as Leu-1 and OKT 8.
|
3097073 |
1986 |
|
Lymphocytosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Tumors associated with peripheral lymphocytosis more commonly expressed the Leu-1 antigen (P less than 0.01) and IgD (P less than 0.01) and less frequently were stained by BA-2 (P less than 0.05) and OKT9 (P less than 0.05).
|
3322023 |
1987 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Flow cytometric analysis of forward- and right-angle light scatters demonstrated the presence of two populations of cells, one lymphoid, bearing predominantly lambda light chain surface immunoglobulin and showing phenotypic characteristics of B cell chronic lymphocytic leukemia (HLA-DR-positive, BL-1-positive, BL-2-positive, BL-7-positive, Leu-1-positive, Leu-10-positive, BL-5-negative, BL-6-negative, and OKM1-negative), and another granulocytic population expressing phenotypic features compatible with myeloid lineage (HLA-DR-negative, Leu-1-negative, BL-1-negative, BL-2-negative, BL-7-negative, Leu-10-negative, BL-5-positive, BL-6-negative, OKM1-positive, and surface immunoglobulin-negative).
|
3456199 |
1986 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.050 |
Biomarker
|
disease |
BEFREE |
Flow cytometric analysis of forward- and right-angle light scatters demonstrated the presence of two populations of cells, one lymphoid, bearing predominantly lambda light chain surface immunoglobulin and showing phenotypic characteristics of B cell chronic lymphocytic leukemia (HLA-DR-positive, BL-1-positive, BL-2-positive, BL-7-positive, Leu-1-positive, Leu-10-positive, BL-5-negative, BL-6-negative, and OKM1-negative), and another granulocytic population expressing phenotypic features compatible with myeloid lineage (HLA-DR-negative, Leu-1-negative, BL-1-negative, BL-2-negative, BL-7-negative, Leu-10-negative, BL-5-positive, BL-6-negative, OKM1-positive, and surface immunoglobulin-negative).
|
3456199 |
1986 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We studied 81 cases of ALL using immunoperoxidase stain for nuclear terminal deoxynucleotidyl transferase (TdT) and immunoalkaline phosphatase stain for surface markers (using monoclonal antibody J5 for common ALL antigen [CALLA], Leu-1 for pan-T antigen, and B1 for pan-B antigen) on air-dried smears.
|
3472463 |
1987 |
|
Leukemia, T-Cell, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
A case of T-cell chronic lymphocytic leukemia (T-CLL) expressing a peculiar phenotype (E+, OKM1+, Leu 1+, OKT3- and IgG EA-).
|
6193857 |
1983 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The majority of ATLL cells bear Leu-1 and Leu-3a antigen on cell surface but lack Leu-2a antigen and were unreactive with MAS 036 c. These results indicate that ATLL cells are of peripheral inducer/helper T-cell origin.
|
6600211 |
1983 |
|
Lymphoma, T-Cell, Cutaneous
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Subtypes of cutaneous T-cell lymphoma defined by expression of leu-1 and Ia.
|
7042004 |
1982 |
|
Hodgkin Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Quantitative immunophenotypic analysis of 13 cases revealed a predominance of Leu1 and Leu3 T cells in all subtypes, except in the case of HD lymphocytic-depression (HDLD).
|
8395909 |
1993 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.
|
9395242 |
1997 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.050 |
Biomarker
|
disease |
BEFREE |
We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.
|
9395242 |
1997 |
|
leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Two adjacent genes, termed Leu1 and Leu2 (leukemia-associated gene 1 and 2), were mapped to the minimally deleted region, with several patients showing deletion borders within these genes.
|
9395242 |
1997 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.
|
9395242 |
1997 |